<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296021</url>
  </required_header>
  <id_info>
    <org_study_id>KY20140916-2</org_study_id>
    <nct_id>NCT02296021</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy</brief_title>
  <official_title>Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating efficacy and safety of berberine-containing quadruple&#xD;
      therapy(berberine, esomeprazole, clarithromycin and amoxicillin) versus bismuth-containing&#xD;
      quadruple therapy (bismuth,esomeprazole,clarithromycin and amoxicillin) in H. pylori&#xD;
      eradication. It is hypothesized that berberine-containing quadruple therapy is non-inferior&#xD;
      to bismuth-containing quadruple therapy. Patients with confirmed H. pylori positive status&#xD;
      will be randomized to one of the treatments described above. At week 2 and 6 follow-up&#xD;
      visits, a urea breath test(UBT) will be performed to confirm eradication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up. Screening: this&#xD;
      phase will last a maximum of 28 days and subjects eligibility will be evaluated after&#xD;
      informed consent signature. Endoscopy and Urea Breath test will be performed in addition to&#xD;
      the baseline routine evaluations.&#xD;
&#xD;
      Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A&#xD;
      randomization visit will take place on Day 0 and an end-of-treatment visit will take place&#xD;
      between day 12 and 14.&#xD;
&#xD;
      Follow-up: includes two visits. approximately 14 days of treatment and 28 days after the end&#xD;
      of treatment. Eradication of H. Pylori will be confirmed through urea breath test(UBT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>The primary end point of this study is H.pylori eradication,established by negative [13C] urea breath test 28 days after the end of eradication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms effective rates</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Evaluation effective rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment.&#xD;
Symptom effective rate =（total score before treatment - total score after treatment）/total score before treatment x 100%. Total score = frequency + severity.&#xD;
Frequency score is calculated by all the frequency of heartburn,reflux,abdominal pain,and flatulence. Severity is accumulated by the degree of symptoms described above,which is divided to 4 degree as 0 presenting none,and 3 presenting most severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache,dizziness,skin rash,other gastrointestinal disorders,pyrexia,cough and back pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Gastritis</condition>
  <condition>Peptic Ulcer</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.</description>
    <arm_group_label>bismuth quadruple therapy</arm_group_label>
    <other_name>Bitnal</other_name>
    <other_name>colloidal bismuth tartrate capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>bismuth quadruple therapy</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>bismuth quadruple therapy</arm_group_label>
    <other_name>Amoxy ( Uni-Amocin )</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <description>Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.</description>
    <arm_group_label>berberine quadruple therapy</arm_group_label>
    <arm_group_label>bismuth quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18~70,both gender.&#xD;
&#xD;
          2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.&#xD;
&#xD;
          3. Patients are willing to receive eradication treatment.&#xD;
&#xD;
          4. Women are eligible if they are not pregnant or nursing, and if they are of&#xD;
             childbearing potential they are required to use medically acceptable contraception for&#xD;
             the duration of the study and 30 days thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are excluded if they have previously used antibiotics to eradicate adequately&#xD;
             recorded infection with H. pylori.&#xD;
&#xD;
          2. Contraindications to study drugs.&#xD;
&#xD;
          3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.&#xD;
&#xD;
          4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI)&#xD;
             within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes&#xD;
             (more than 3 times /1 month before screening)&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Underwent upper gastrointestinal Surgery.&#xD;
&#xD;
          7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of&#xD;
             dysphagia.&#xD;
&#xD;
          8. Evidence of bleeding or iron eficiency anemia.&#xD;
&#xD;
          9. A history of malignancy.&#xD;
&#xD;
         10. Drug or alcohol abuse history in the past 1 year.&#xD;
&#xD;
         11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,&#xD;
             anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less&#xD;
             than 100 mg/d).&#xD;
&#xD;
         12. Enrolled in other clinical trials in the past 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongquan Shi, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Professor/Chief Physician</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>berberine-containing quadruple therapy</keyword>
  <keyword>bismuth-containing quadruple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

